, Volume 31, Issue 8, pp 1259-1261
Date: 27 May 2012

Rituximab in a patient with ankylosing spondylitis with demyelinating disease: a case report and review of the literature

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Tumor necrosis factor inhibitors (TNFI) are novel therapies used to treat ankylosing spondylitis (AS). Demyelinating disease is a rare but serious complication of TNFI. We report a patient with a case of AS who developed demyelinating disease secondary to TNFI and was treated successfully with rituximab.